Quantum Cyber N.V.
Berkeley, California, United States · Biotechnology, Cyber Security, Health Care
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently
Key facts
- Headquarters
- Berkeley, California, United States
- Employees
- Unknown
- Industries
- Biotechnology, Cyber Security, Health Care
- Status
- Public (QUCY)
- Website
- mainzbiomed.com
- Company page
Recent activity at Quantum Cyber N.V.
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On October 9, 2026, Quantum Cyber N.V. entered into a Sales Agreement with Titan Partners Securities LLC to establish an 'at the market' offering program. Under this agreement, the company can sell up to $100,000,000 of its ordinary shares, nominal value €0.01 each. This arrangement allows the shares to be issued and sold through the Agent as per the provisions of the company's previously filed shelf Registration Statement on Form S-3. The strategic move aims to secure additional funding through capital markets under favorable conditions.
- : SEC 8-K (7.01): On September 25, 2026, Quantum Cyber N.V. issued a press release regarding a sharpened strategic focus and the update of its corporate investor presentation. The press release was made available in the filing as Exhibit 99.1, alongside an investor presentation (Exhibit 99.2) intended for upcoming meetings with investors or analysts. This focuses on the company's ongoing strategic initiatives and aims to enhance communication with stakeholders about its corporate strategies and goals. The action reflects an effort to engage more effectively with investors amid changing market conditions.
- : SEC 8-K (7.01):
- : SEC 8-K (2.01): On July 15, 2026, Quantum Drones Corporation completed the acquisition of certain parcels of real property located at 38 Union Avenue, Bridgeport, Connecticut, for an aggregate purchase price of $2,300,000. This acquisition was made possible through a Purchase and Sale Agreement with Arcade Realty LLC, following the execution of an Asset Purchase Agreement with Arcade Technology LLC on June 26, 2026. The completion of this transaction signifies a strategic expansion for Quantum Drones, potentially enhancing their operational footprint in the region and aligning with their growth objectives.
- : SEC 8-K (5.02): On July 6, 2026, Quantum Cyber N.V. appointed Peter O'Rourke as the President of its wholly owned subsidiary, Quantum Drones Corporation, pursuant to an Employment Agreement effective from July 1, 2026. The agreement stipulates a monthly base salary of $20,833.33, reduced to $16,666.67 for the remainder of 2026 due to previous compensation as a director. Additionally, O'Rourke will receive stock options for 112,859 shares at an exercise price of $1.45 per share. The agreement includes provisions for severance, confidentiality, and other customary clauses, emphasizing performance reviews for potential salary increases. This management change is significant for Quantum Drones' operational leadership, following a strategic initiative to strengthen its executive team.
- : Quantum Cyber to acquire Arcade Metal Stamping factory
- : SEC 8-K (1.01):
- : SEC 8-K (1.01):
- : SEC 8-K (1.02): On June 2, 2026, Quantum Cyber N.V. notified Maxim Group LLC to terminate their at-the-market issuance sales agreement, effective June 7, 2026. The Sales Agreement, originally dated October 1, 2025 and recently amended on May 4, 2026, had allowed the sale of 3,280,927 Ordinary Shares, generating net cash proceeds of approximately $4,388,515 prior to its termination. There are no penalties associated with this termination. This decision reflects a strategic shift in Quantum Cyber's sales approach, potentially impacting its capital raising strategy moving forward.
Quantum Cyber N.V. funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2026 | Post-IPO Equity | $4.4M |
| Jul 2023 | Venture | $5.5M |
| Sep 2021 | Seed | $603K |
Leadership
- Marco Messina, Director
- Nicole Holden, Director
- Heiner Dreismann, Director
- Moritz Eidens, Executive Officer
- Guido Baechler, Executive Officer
- William Caragol, Executive Officer
Verified email and direct lines for Quantum Cyber N.V.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Quantum Cyber N.V. in the news
- Mainz Biomed appoints new chairman, rebrands as Quantum Cyber - Investing.com (Mar 11, 2026)
- Mainz Biomed N.V. Announces Name Change to Quantum Cyber N.V. and New Ticker Symbol "QUCY" on Nasdaq - Quiver Quantitative (Mar 13, 2026)
- Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors - Yahoo Finance (Mar 11, 2026)
- Defense tech company’s Bridgeport factory deal moves toward closing - Hartford Business Journal (Jul 02, 2026)
- Quantum Cyber N.V. News — NASDAQ:QUCY - TradingView (Mar 13, 2026)
- Quantum Cyber (Nasdaq:QUCY) - Stock Analysis - Simply Wall St (May 01, 2026)
- Mainz Biomed (QUCY) Stock Price, News & Analysis - MarketBeat (Mar 13, 2026)
Companies similar to Quantum Cyber N.V.
- Optimize Systems · Biotechnology, Health Care, Health Diagnostics, Information Technology, Medical
- RapidAI · Biotechnology, Health Care, Health Diagnostics, Information Technology, Medical
- LifeSignals · Biotechnology, Health Care, Health Diagnostics, Information Technology, Medical
- RADPAIR · Biotechnology, Health Care, Health Diagnostics, Information Technology, Medical
- TeleRay · Biotechnology, Health Care, Health Diagnostics, Information Technology, Medical
About Quantum Cyber N.V.: questions and answers
What does Quantum Cyber N.V. do?
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert® is currently
Where is Quantum Cyber N.V. headquartered?
Quantum Cyber N.V. is headquartered in Berkeley, California, United States.
Has Quantum Cyber N.V. raised funding?
Yes. Fundz has recorded 3 funding events for Quantum Cyber N.V.. The most recent, Post-IPO Equity of $4.4M, was in Jun 2026.
What is the latest news on Quantum Cyber N.V.?
On Oct 12, 2026, SEC 8-K (5.02):
Is Quantum Cyber N.V. a public company?
Yes. Quantum Cyber N.V. is publicly traded under the ticker QUCY.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy